Clinical trial
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).
NCT03348527 is registered in ClinicalTrials.gov with Lidds AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).
- Lead sponsor
- Lidds AB
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 12, 2017
- Completion date
- November 30, 2020
- Enrollment
- 61 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer